Literature DB >> 23680870

Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type.

P Savini1, A Lanzi, F G Foschi, G Marano, G F Stefanini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23680870     DOI： 10.1007/s00277-013-1787-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Authors:  Kai Xue; Juan J Gu; Qunling Zhang; Cory Mavis; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman; Ye Guo
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-28       Impact factor: 4.553

2.  [Management of cutaneous lymphomas].

Authors:  J P Nicolay; C-D Klemke
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

3.  Relapsed Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type.

Authors:  Shaohua Wu; Wei Gui; Liping Su; Yanfeng Xi
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

4.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 5.  MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.

Authors:  Rongrong Chen; Lulu Wang; Lixia Zhu; Xiujin Ye
Journal:  Ther Adv Hematol       Date:  2022-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.